BACKGROUND
==========

Type 2 diabetes mellitus (T2DM) is one of the most important problems in the world and patients with T2DM are at an increased risk for a number of serious health problems, including cardiovascular disease, premature death, blindness, kidney failure, amputations and cognitive decline \[[@sfy122-B1]\]. Chronic kidney disease (CKD) with a glomerular filtration rate (GFR) of \<60 mL/min/1.73 m^2^ is a common condition estimated to affect 8.6--14.5% of the Thai population, and 28.5% have both T2DM and CKD \[[@sfy122-B2], [@sfy122-B3]\]. Diabetes is often associated with CKD, and for 30--40% of patients receiving dialysis therapy, diabetes is the primary cause of end-stage renal disease. Optimized glucose control reduces the risk of diabetic micro- and macrovascular complications \[[@sfy122-B4], [@sfy122-B5]\].

One recently approved class of glucose-lowering drugs inhibits sodium-glucose cotransporter type 2 (SGLT2) in the renal proximal tubule and hence reduces renal reabsorption of filtered glucose, resulting in substantial glycosuria \[[@sfy122-B6]\]. Clinical studies on SGLT2 inhibitors have reported reductions in glycated hemoglobin A1c (HbA1c) levels compared with placebo and other glucose-lowering strategies \[[@sfy122-B7], [@sfy122-B8]\] and a reduction in cardiovascular mortality in individuals with T2DM, as well as a significantly lower risk of worsening nephropathy, progression to macroalbuminuria, doubling of serum creatinine levels and initiation of renal replacement therapy in high cardiovascular-risk patients \[[@sfy122-B9]\].

SGLT2 inhibitors represent a promising therapeutic approach to preventing and improving nephropathy in patients with T2DM. Current data strongly support that SGLT2 inhibitors have renoprotective properties not only by improving glycemic control, but also through hemodynamic and nonhemodynamic renal effects \[[@sfy122-B10]\]. A study using diabetic endothelial nitric oxide synthase (eNOS) knockout mice demonstrated the effect of SGLT2 inhibition on diabetic nephropathy, independent of blood glucose lowering \[[@sfy122-B11]\]. Moreover, initial studies reported that SGLT2 inhibition decreased the production of inflammatory and fibrotic markers induced by high glucose levels in human proximal tubular cells \[[@sfy122-B12]\]. These *in vitro* findings suggest that SGLT2 inhibitors may provide renoprotection in diabetes by preventing glucose from entering proximal tubule cells \[[@sfy122-B13], [@sfy122-B14]\]. Thus, in this study, we aimed to determine whether administration of dapagliflozin, an SGLT2 inhibitor, influences proximal tubular cell injuries and function in T2DM patients.

MATERIALS AND METHODS
=====================

Subjects
--------

This was a randomized, open-label, controlled study conducted over 12 weeks in T2DM patients at Phramongkutklao Hospital, Bangkok, Thailand between 15 January 2015 and 16 December 2016. The study was approved by the institutional review boards of Phramongkutklao Hospital and the College of Medicine. Using blocks of four randomizations, patients were assigned to one of two double-blinded treatment groups. A computer-generated randomization procedure in blocks of four was used. Inclusion criteria comprised age ≥18 years, a diagnosis of T2DM, an estimated GFR (eGFR) \>60 mL/min/1.73 m^2^, stable glycemic treatment with HbA1c levels between 7% and 10% at least 3 months before and no treatment adjusted with antihypertensive drugs within 3 months of starting the study. Exclusion criteria included a history of urinary and genital tract infection, dehydration, a history of diabetic ketoacidosis, use of loop diuretics, pregnancy and any uncontrolled endocrine disorders within 1 year of starting the study. All subjects gave their informed consent before they were enrolled.

Eligible patients were randomly assigned to two groups. One group consisted of 29 patients treated with standard glycemic treatment for T2DM, while the other group consisted of 28 patients treated with dapagliflozin 10 mg/day orally. During the 12 weeks in the control group, patients had their hypoglycemic medications adjusted to maintain HbA1c levels at \<7--8%. All patients typically continued with their normal daily activities during both treatments and were instructed to adhere to a disease- and weight-oriented diet and exercise regimen throughout the study.

All subjects underwent laboratory blood tests at baseline and at 12 weeks at the end of the study. All patients were monitored for proximal tubular injury biomarkers, including urine kidney injury molecule-1:creatinine ratio (UKIM1CR), urine cystatin C:creatinine ratio (UCCR), urine albumin:creatinine ratio (UACR), fractional excretion of sodium (FENa), fractional excretion of phosphate (FEPO~4~) and fractional excretion of uric acid (FEUA). Serum and urine samples were also obtained after overnight fasting and were immediately processed for analysis, including fasting plasma glucose (FPG), HbA1c, blood urea nitrogen, creatinine, complement blood count and urinary analysis. Other conventional parameters, including body weight, systolic and diastolic blood pressure, symptoms and signs related to drug reactions and compliance with medications were closely monitored every 4 weeks.

Safety monitoring
-----------------

Adverse events that were considered related to dapagliflozin treatment were monitored for at 4 and 12 weeks. The patients were questioned each time in a systematic way about their experiences concerning adverse events, especially ketoacidosis and genital and urinary tract infections, over the 12 weeks. We evaluated the incidence of renal progression using assessments of renal function over time with serum creatinine levels and eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation.

Statistical analyses
--------------------

Statistical analyses were performed using Stata version 13.0 (StataCorp, College Station, TX, USA). Descriptive statistics were used to summarize the demographics and baseline characteristics. Comparability of treatment groups was assessed using a two-way analysis of variance (ANOVA). Data were presented as mean ± standard error (SE) and mean change. Differences between groups were established using the independent *t-*test. Repeated measures ANOVA was used to compare the results to baseline at each time point for each of the efficacy parameters. All results were considered significant if P \< 0.05.

RESULTS
=======

A total of 68 patients from outpatient clinics were screened for possible study enrollment. Fifty-seven patients were eligible according to the study entry criteria shown in [Figure 1](#sfy122-F1){ref-type="fig"}. Overall, 28 patients were assigned to the dapagliflozin group (10 mg/day) and 29 patients to the standard treatment group. Characteristics of the study population are shown in [Table 1](#sfy122-T1){ref-type="table"}. The baseline characteristics of the treatment and placebo groups did not differ in terms of age, gender, body weight, body mass index, blood pressure, current medications, comorbid diseases and medications. In total, 76% of the patients were taking statins or fibrates at baseline.

![Flowchart of the study.](sfy122f1){#sfy122-F1}

###### 

Baseline characteristics of patients

  Parameter                          Dapagliflozin    Control     P-value
  --------------------------------- --------------- ------------ ---------
  Male, *n* (%)                        17 (60.7)       8 (27)      0.012
  Age (years)                         55.9 ± 1.4     59.9 ± 1.6    0.059
  Duration of T2DM (years)             8.5 ± 0.9     9.0 ± 1.0     0.685
  Systolic blood pressure (mmHg)      134.8 ± 2.4    131 ± 2.7     0.302
  Diastolic blood pressure (mmHg)     79.8 ± 2.5     75.7 ± 2.2    0.221
  Body weight (kg)                    75.3 ± 2.4     68.7 ± 2.5    0.061
  Body mass index (kg/m^2^)           28.4 ± 0.8     27.9 ± 0.9    0.692
  UACR ≥30 mg/g Cr, *n* (%)            11 (39.3)      8 (27.6)     0.349
  Comorbid diseases, *n* (%)                                     
   Hypertension                        23 (82.1)     26 (89.7)   
   Cerebrovascular disease              2 (7.1)       1 (3.5)      0.532
   Dyslipidemia                        26 (92.9)     28 (96.6)     0.532
   Cardiovascular disease               1 (3.6)       5 (17.2)     0.093
   Diabetic retinopathy                4 (14.3)       5 (17.2)     0.760
  Medications, *n* (%)                                           
   RAAS inhibitors                     19 (67.9)     15 (51.7)     0.215
   Beta-blockers                       6 (21.4)       9 (31.0)     0.410
   Calcium channel blockers            10 (35.7)     15 (51.7)     0.223
   Metformin                           25 (89.3)     26 (89.7)     0.964
   Sulfonylurea                        16 (57.1)     14 (48.3)     0.503
   Insulin                             5 (17.9)       6 (20.7)     0.786

Data are presented as mean ± SE unless stated otherwise. Cardiovascular disease was defined as coronary heart disease, peripheral artery disease and heart failure. Cerebrovascular disease was defined as ischemic and nonischemic stroke.

RAAS, renin--angiotensin--aldosterone system.

Changes in metabolic, glycemic and laboratory parameters
--------------------------------------------------------

At the end of 12 weeks, body weight was significantly decreased at 1.0 ± 0.4 kg from baseline in the dapagliflozin group (P \< 0.05), but there was no difference in mean changes in body weight between the two groups. The mean FPG level significantly decreased from 179.9 ± 9.7 to 157.8 ± 9.5 mg/dL in the dapagliflozin group (P \< 0.05) and from 168.3 ± 10.8 to 155.1 ± 9.2 mg/dL in the control group (P \< 0.05). Similarly, the mean HbA1c level significantly decreased from 8.7 ± 0.2 to 7.9 ± 0.2% in the dapagliflozin group (P \< 0.05) and from 8.6 ± 0.2 to 7.9 ± 0.2% in the control group (P \< 0.05). No difference was observed between the two groups regarding FPG and HbA1c levels at baseline or at the study end or in the change in these values during the study ([Table 2](#sfy122-T2){ref-type="table"}). The mean hemoglobin level increased after treatment with dapagliflozin and there was a significant difference in increased mean changes in hemoglobin level between the two groups. In contrast, blood pressure and the levels of serum uric acid, phosphate, low-density lipoprotein (LDL) cholesterol and triglycerides did not significantly change in either group throughout the study ([Table 2](#sfy122-T2){ref-type="table"}).

###### 

Changes in metabolic, glycemic and laboratory parameters after 12 weeks of treatment

  Parameter                          Dapagliflozin (*n* = 28)   Control (*n* = 29)   P-value
  --------------------------------- -------------------------- -------------------- ---------
  Body weight (kg)                                                                  
   Baseline                                 75.3 ± 2.4              68.7 ± 2.5        0.061
   Week 12                                  74.2 ± 2.5              68.2 ± 2.7        0.110
   Change from baseline                   --1.0 ± 0.4\*            --0.1 ± 0.4        0.081
  Fasting plasma glucose (mg/dL)                                                    
   Baseline                                179.9 ± 9.7             168.3 ± 10.8       0.429
   Week 12                                 157.8 ± 2.5             155.2 ± 9.2        0.844
   Change from baseline                   --19.6 ± 8.2\*           --11.1 ± 8.7       0.481
  HbA1c (%)                                                                         
   Baseline                                 8.7 ± 0.2               8.6 ± 0.2         0.533
   Week 12                                  7.9 ± 0.2               7.9 ± 0.3         0.776
   Change from baseline                   --0.7 ± 0.2\*            --0.7 ± 0.3        0.882
  Hemoglobin (g/dL)                                                                 
   Baseline                                 13.5 ± 0.3              12.5 ± 0.2        0.020
   Week 12                                  14.1 ± 0.3              12.6 ± 0.3        0.000
   Change from baseline                     0.5 ± 0.1              --0.1 ± 0.1        0.002
  Systolic blood pressure (mmHg)                                                    
   Baseline                                134.8 ± 2.4             131.0 ± 2.7        0.302
   Week 12                                 132.8 ± 2.3             133.4 ± 2.8        0.870
   Change from baseline                    --2.0 ± 2.8              3.3 ± 2.1         0.146
  Diastolic blood pressure (mmHg)                                                   
   Baseline                                 79.8 ± 2.5              75.7 ± 2.2        0.221
   Week 12                                  79.9 ± 1.5              76.0 ± 2.1        0.140
   Change from baseline                     0.2 ± 2.3               0.6 ± 2.0         0.889
  Serum phosphate (mg/dL)                                                           
   Baseline                                 3.2 ± 0.1               3.3 ± 0.1         0.259
   Week 12                                  3.5 ± 0.1               3.4 ± 0.2         0.861
   Change from baseline                     0.3 ± 0.1               0.1 ± 0.2         0.370
  Serum uric acid (mg/dL)                                                           
   Baseline                                 5.2 ± 0.2               4.9 ± 0.3         0.605
   Week 12                                  5.2 ± 0.3               5.3 ± 0.3         0.650
   Change from baseline                    --0.1 ± 0.2              0.2 ± 0.1         0.265
  Triglycerides (mg/dL)                                                             
   Baseline                                145.0 ± 14.0            161.1 ± 16.7       0.463
   Week 12                                 142.1 ± 13.4            154.7 ± 17.6       0.570
   Change from baseline                    --6.1 ± 12.9            --7.1 ± 10.0       0.950
  LDL cholesterol (mg/dL)                                                           
   Baseline                                102.5 ± 6.6              87.9 ± 4.9        0.080
   Week 12                                 104.0 ± 5.3              89.3 ± 6.5        0.085
   Change from baseline                     1.3 ± 6.4              --1.8 ± 4.5        0.949

Data are mean ± SE. Week 12 values compared with baseline. \*P \< 0.05.

Proximal tubular injury biomarkers and renal function
-----------------------------------------------------

After 12 weeks of treatment, the mean UACR significantly decreased from 51.1 ± 14.2 to 37.3±9.4 mg/g Cr (P = 0.032) in the dapagliflozin group and there was a significant between-group difference in the reduction of UACR {−23.3 \[95% confidence interval (CI) −44.4 to −2.2\] versus +19.9 (−4.0--43.8) mg/g Cr; P = 0.010} and in percentage change in UACR (−26.8 ± 11.5 versus 51.3 ± 33.4%; P = 0.036) ([Figure 2](#sfy122-F2){ref-type="fig"}). Similarly, the mean UKIM1CR decreased from 502.7 ± 106.8 to 338.4 ± 85.7 mg/g Cr (P = 0.789) in the dapagliflozin group and significantly increased from 563.3 ± 117.2 to 910.5 ± 230.6 mg/g Cr in the control group (P = 0.029). There were significant between-group differences in the reduction of UKIM1CR \[−26.7 (95% CI −232.9--179.5) versus + 422.2 (46.7--797.7) ng/g Cr; P = 0.047\] and in the percentage change in UKIM1CR (92.3 ± 56.7 versus 248.2 ± 78.0%; P = 0.128) ([Figure 2](#sfy122-F2){ref-type="fig"}). UCCR significantly increased in both groups during the study, but there was no significant difference in the mean change in UCCR between the two groups. There was no significant change in serum creatinine levels, GFR, FENa, FEUA and FEPO~4~ in either treatment group ([Table 3](#sfy122-T3){ref-type="table"}).

![Mean and percentage changes in UACR and UKIM1CR after 12 weeks of treatment. There were no significant changes in mean UACR and UKIM1CR from baseline in both control and dapagliflozin treatment groups, but significantly increased UKIM1CR in the control treatment group. There were significant between-group differences in the mean changes in (**A**) UACR and (**B**) KIM1CR (P \< 0.05). There was (**C**) a significant between-group difference in the percentage changes of UACR (P = 0.036) but (**D**) no significant between-group difference in the percentage changes of UKIM1CR (P = 0.128).](sfy122f2){#sfy122-F2}

###### 

Changes in renal function and levels of proximal tubular biomarkers after 12 weeks of treatment

  Renal parameters            Dapagliflozin (*n* = 28)    Control (*n* = 29)     P-value
  -------------------------- -------------------------- ----------------------- ---------
  Serum creatinine (mg/dL)                                                      
   Baseline                          0.9 ± 0.0                 0.8 ± 0.0          0.309
   Week 12                           0.9 ± 0.1                 0.8 ± 0.1          0.381
   Change from baseline              0.0 ± 0.0                 0.0 ± 0.0          0.982
  eGFR (mL/min/1.73 m^2^)                                                       
   Baseline                          88.7 ± 3.1               87.3 ± 2.9          0.747
   Week 12                           87.4 ± 3.3               85.3 ± 3.2          0.653
   Change from baseline            --1.0 ± 1.4\*              --1.9 ± 1.9         0.695
  UACR (mg/g Cr)                                                                
   Baseline                      51.1 (22.0--80.1)       127.4 (--75.4--330.1)    0.456
   Week 12                       36.7 (12.1--61.4)         46.5 (10.7--82.4)      0.677
   Change from baseline       --23.3 (--44.4 to --2.2)    19.9 (--4.0--43.8)      0.010
  UKIM1CR (ng/g Cr)                                                             
   Baseline                        502.7 ± 106.8             563.3 ± 117.2        0.705
   Week 12                          338.4 ± 85.7             910.5 ± 230.6        0.028
   Change from baseline       --26.7 (--232.9--179.5)     422.2 (46.7--797.7)     0.047
  UCCR (mcg/gCr)                                                                
   Baseline                          12.5 ± 2.6               15.8 ± 3.4          0.455
   Week 12                           27.8 ± 6.1               29.4 ± 4.9          0.841
   Change from baseline             15.3 ± 7.2\*             14.1 ± 5.7\*         0.898
  FEPO~4~ (%)                                                                   
   Baseline                          11.6 ± 0.8               11.3 ± 0.9          0.826
   Week 12                           10.8 ± 1.1               10.8 ± 2.9          0.986
   Change from baseline             --0.7 ± 0.9               --0.6 ± 3.1         0.959
  FEUA (%)                                                                      
   Baseline                          9.1 ± 0.7                 9.8 ± 0.8          0.525
   Week 12                           8.8 ± 0.7                 7.0 ± 0.5          0.046
   Change from baseline             --0.1 ± 0.8               --1.3 ± 0.6         0.130
  FENa (%)                                                                      
   Baseline                          1.1 ± 0.2                 1.3 ± 0.2          0.473
   Week 12                           1.1 ± 0.2                 1.2 ± 0.2          0.528
   Change from baseline             --0.1 ± 0.2                0.1 ± 0.2          0.619

Data are mean ± SE or mean (95% CI). Week 12 values compared with baseline. \*P \< 0.05.

Adverse events
--------------

No significant acute kidney injury, volume depletion and hypotension in the dapagliflozin group was detected. Finally, there were no reports of urinary tract infections, genital tract infections, ketoacidosis, deaths or drug-related serious adverse events in either group.

DISCUSSION
==========

The present study is a randomized controlled trial of the effect of SGLT2 inhibitors on proximal tubular injuries and function in T2DM patients. Dapagliflozin 10 mg/day as add-on therapy appears as efficacious as standard treatment in terms of improving glycemic control (HbA1c and FPG). Interestingly, dapagliflozin also has inhibitory effects on urine kidney injury molecule-1 (KIM-1) and albuminuria in proximal tubular cells in response to hyperglycemia.

In a recent larger randomized controlled trial, empagliflozin was associated with slower progression of kidney disease and lower rates of new or worsening nephropathy, including macroalbuminuria, doubling of serum creatinine levels with a GFR of \<45 mL/min/1.73 m^2^ and initiation of renal replacement therapy in patients with T2DM at high cardiovascular risk \[[@sfy122-B15]\]. In addition, several clinical studies showed a significant reduction in albuminuria and a slow decline in GFR after the initiation of SGLT2 inhibitors \[[@sfy122-B16]\]. Our study also demonstrated improved albuminuria, the earliest clinical manifestation of diabetic renal injury and which serves as a biomarker of renal and vascular injury in diabetes \[[@sfy122-B19]\]. SGLT2 inhibitors might be able to limit high glucose--induced inflammatory and fibrotic markers, most likely due to blocking glucose entry into proximal tubular cells.

Novel biomarkers of tubulointerstitial changes prove to better predict renal progression and prognosis in T2DM. Tubular biomarkers such as cystatin C, KIM-1, neutrophil gelatinase-associated lipocalin (NGAL) and monocyte chemoattractant protein-1 reflect tubular injury \[[@sfy122-B20], [@sfy122-B21]\]. The effects of SGLT2 inhibitors on markers of tubular injury in patients with T2DM are as yet unknown, with no previous clinical study of SGLT2 inhibitors on biomarkers of proximal tubular injury in patients with T2DM. Proximal tubular basement membrane thickening, hyperplasia and hypertrophy, followed by tubular atrophy, were detected in progressive diabetic kidney injury \[[@sfy122-B22]\]. Interestingly, experimental knockout of SGLT2 in diabetic mice had no effect on the increase in markers of tubular damage such as NGAL and KIM-1 \[[@sfy122-B23]\]. An *in vitro* study using human proximal tubular cells indicated that SGLT2 inhibitors augmented advanced glycation end-product--induced apoptotic death of tubular cells and decreased the level of high glucose--induced inflammatory and fibrotic markers by reducing glucose transport to the proximal tubular cells \[[@sfy122-B12], [@sfy122-B24]\]. Recently, in a post hoc analysis of a crossover trial, dapagliflozin treatment for 6 weeks decreased albuminuria, urinary KIM-1 excretion and urinary interleukin-6 (IL-6) excretion compared with placebo, which could be the result of reduced tubular cell injury \[[@sfy122-B25]\]. Consistent with our findings, dapagliflozin protects against proximal tubular injury and decreases urinary KIM-1 and albuminuria, independent of glycemic control and HbA1c lowering. However, there was no difference in changes in urine cystatin C levels between the two treatment groups. There was a significant increase in urine cystatin C levels after treatment with both the SGLT2 inhibitor and control in our study, but these changes were very small.

In terms of proximal tubular function, FEUA, FEPO~4~ and serum uric acid levels did not significantly change from baseline after 12 weeks of treatment with dapagliflozin. In agreement with a previous study in healthy Japanese men, the greatest change in urinary excretion of uric acid from baseline was observed on day 1, with the magnitude of change decreasing on days 3 and 7 after SGLT2 inhibitor administration \[[@sfy122-B26], [@sfy122-B27]\]. However, dapagliflozin treatment was associated with a small decrease in serum uric acid levels, in line with many previous studies, which could explain the uricosuric effect of SGLT2 inhibitors. Glucose transporter 9 (GLUT9) is a countertransporter that exchanges glucose for uric acid, whereby the two isoforms of the counter-transporter act concertedly to reabsorb glucose from the lumen of the tubule in exchange for uric acid. In the presence of high glucose concentrations on the luminal side, coupled with volume depletion (due to SGLT2 inhibitors), one would expect primary proximal uric acid reabsorption and elevated serum uric acid levels. GLUT9 might counterbalance primary uric acid reabsorption, acting as an efflux transporter of urate from the tubular cells \[[@sfy122-B28]\]. In our study, the uricosuric effect, as demonstrated by FEUA, decreased in both treatment groups and was more marked at week 12 in the control group compared with the dapagliflozin-treated group, but there was no significant difference in the mean change in FEUA between the groups. This probably reflects the low baseline serum uric acid levels and the biochemical interaction between serum glucose and purine metabolism, with decreased excretion of uric acid in the presence of lower plasma glucose levels and glycosuria \[[@sfy122-B29]\].

Several limitations are associated with the present study. First, the long-term outcomes and serious adverse effects in patients with T2DM could not be demonstrated in this study. The study also did not show that the increased levels of urine KIM-1 would be associated with long-term effects on clinical endpoints. Additional research is needed to confirm the results and determine the long-term clinical outcomes. Second, the study included the relative difference in baseline urine albumin between the two groups of patients, and only 50--70% of the patients received renin--angiotensin--aldosterone system inhibition. Third, we did not perform renal histopathology to confirm evidence of proximal tubular injuries. Finally, the study had an open-label, randomized controlled design. The strength of the study stemmed from measurements of several tubular biomarkers, including KIM-1, cystatin C, FEUA and FEPO~4~.

In summary, this study showed that dapagliflozin in T2DM patients decreased urinary levels of proximal kidney injury biomarkers, including KIM-1 and albuminuria, which indicates its renoprotective effects, independent of blood glucose levels and HbA1c lowering. These data suggest that SGLT2 inhibitors might ameliorate glucose toxicity on proximal tubular cells, leading to potential long-term renoprotective effects in T2DM patients. Large long-term clinical trials are needed to confirm the main renal benefits of SGLT2 inhibitors in terms of the development of tubular injury in diabetic nephropathy.
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